Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.79 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.79 |
| ▸ | ADK | P55263 | 1/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.66 |
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
| ▸ | HTR6 | P50406 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16941466 | 1.00 | METTL3 (0.79) | METTL3METTL14ADKADORA3SLC29A1 | |
| SCHEMBL15570446 | 1.00 | METTL3 (0.79) | METTL3METTL14ADKADORA3SLC29A1 | |
| SCHEMBL15477886 | 0.85 | DNPH1 (0.77) | METTL3METTL14ADKADORA3SLC29A1 | |
| SCHEMBL16930356 | 0.85 | DNPH1 (0.77) | METTL3METTL14ADKADORA3SLC29A1 | |
| SCHEMBL16941464 | 0.85 | DNPH1 (0.77) | METTL3METTL14ADKADORA3SLC29A1 | |
| SCHEMBL31237241 | 0.85 | ADK (0.74) | METTL3METTL14ADKSLC29A1 | |
| SCHEMBL14075944 | 0.85 | ADK (0.74) | METTL3METTL14ADKSLC29A1 | |
| SCHEMBL4422764 | 0.85 | ADK (0.74) | METTL3METTL14ADKSLC29A1 | |
| N6-Benzyladenosine SCHEMBL23982413 | 0.84 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A | |
| N6-Benzyladenosine SCHEMBL219439 | 0.84 | ADORA3 (1.00) | ADORA3SLC29A1TP53TDP1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150209379-A1 | TREATMENT OF PROSTATE CANCER AND HEMATOLOGIC NEOPLASMS | THOMAS JEFFERSON UNIVERSITY (US) | 2015-07-30 | — | — | US | claimed |
| WO-2014028080-A1 | TREATMENT OF PROSTATE CANCER AND HEMATOLOGIC NEOPLASMS | THOMAS JEFFERSON UNIVERSITY (US) | 2014-02-20 | — | — | WO | claimed |
| US-20150209379-A1 | TREATMENT OF PROSTATE CANCER AND HEMATOLOGIC NEOPLASMS | THOMAS JEFFERSON UNIVERSITY (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150209379-A1 | TREATMENT OF PROSTATE CANCER AND HEMATOLOGIC NEOPLASMS | THOMAS JEFFERSON UNIVERSITY (US) | 2015-07-30 | — | — | US | disclosed |
| WO-2014028080-A1 | TREATMENT OF PROSTATE CANCER AND HEMATOLOGIC NEOPLASMS | THOMAS JEFFERSON UNIVERSITY (US) | 2014-02-20 | — | — | WO | disclosed |
| WO-2014028080-A1 | TREATMENT OF PROSTATE CANCER AND HEMATOLOGIC NEOPLASMS | THOMAS JEFFERSON UNIVERSITY (US) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209379-A1 | TREATMENT OF PROSTATE CANCER AND HEMATOLOGIC NEOPLASMS | MTAP, DPYD, PNP | METTL3 57/4885METTL14 768/4885ADK 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.